Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 879-887

  Moss, Darren M ^a   Kwan, Wai San ^a   Liptrott, Neill J ^b   Smith, Darren L ^a   Siccardi, Marco ^a   Khoo, Saye H ^a   Back, David J ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; RALTEGRAVIR; SLC10A1; SLC22A6 PROTEIN; SLCO1B3 PROTEIN; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL STRAIN CACO 2; CEM CELL LINE; CONTROLLED STUDY; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; KIDNEY CELL; NONHUMAN; OOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; XENOPUS LAEVIS;

ADENINE; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE; DRUG INTERACTIONS; HIV INTEGRASE INHIBITORS; HUMANS; KIDNEY; LEUKOCYTES, MONONUCLEAR; OOCYTES; ORGANIC ANION TRANSPORT PROTEIN 1; PHOSPHONIC ACIDS; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTRATE SPECIFICITY; XENOPUS LAEVIS;

EID: 78751692552     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00623-10     Document Type: Article

References (43)

1. Anderson, M. S., T. N. Kakuda, W. Hanley, J. Miller, J. T. Kost, R. Stoltz, L. A. Wenning, J. A. Stone, R. M. Hoetelmans, J. A. Wagner, and M. Iwamoto. 2008. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob. Agents Chemother. 52:4228-4232.
2. Anderson, M. S., V. Sekar, F. Tomaka, J. Mabalot, R. Mack, L. Lionti, S. Zajic, L. Wenning, C. Vanden Abeele, M. Zinny, N. M. Lunde, B. Jin, J. A. Wagner, and M. Iwamoto. 2008. Pharmacokinetic (PK) evaluation of darunavir/ritonavir (DRV/r) and raltegravir (RAL) in healthy subjects, abstr. A-962. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
3. Andrews, E., P. Glue, J. Fang, P. Crownover, R. Tressler, and B. Damle. 2008. A pharmacokinetic study to evaluate an interaction between maraviroc and raltegravir in healthy adults, abstr. H-4055. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
4. Barau, C., C. Delaugerre, J. Braun, N. de Castro, V. Furlan, I. Charreau, L. Gerard, C. Lascoux-Combe, J. M. Molina, and A. M. Taburet. 2010. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob. Agents Chemother. 54:937-939.
5. Bleasby, K., J. C. Castle, C. J. Roberts, C. Cheng, W. J. Bailey, J. F. Sina, A. V. Kulkarni, M. J. Hafey, R. Evers, J. M. Johnson, R. G. Ulrich, and J. G. Slatter. 2006. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963-988.
6. Brainard, L. M., A. S. Petry, L. Fang, C. Liu, S. A. Breidinger, E. P. DeNoia, J. A. Stone, J. A. Chodakewitz, L. A. Wenning, J. A. Wagner, and M. Iwamoto. 2009. Lack of a clinically important effect of rifabutin (RFB) on raltegravir (RAL) pharmacokinetics, abstr. A1-1296. Abstr. 49th Annu. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
7. Calcagno, A., S. Bonora, R. Bertucci, A. Lucchini, A. D'Avolio, and G. Di Perri. 2010. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS (London) 24:931-932.
8. Chirch, L. M., S. Morrison, and R. T. Steigbigel. 2009. Treatment of HIV infection with raltegravir. Expert Opin. Pharmacother. 10:1203-1211.
9. Dixit, V., N. Hariparsad, F. Li, P. Desai, K. E. Thummel, and J. D. Unadkat. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35:1853-1859.
10. Elsby, R., D. D. Surry, V. N. Smith, and A. J. Gray. 2008. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38:1140-1164.
11. Espeseth, A. S., P. Felock, A. Wolfe, M. Witmer, J. Grobler, N. Anthony, M. Egbertson, J. Y. Melamed, S. Young, T. Hamill, J. L. Cole, and D. J. Hazuda. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U. S. A. 97:11244-11249.
12. Foisy, M. M., E. M. Yakiwchuk, and C. A. Hughes. 2008. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42:1048-1059.
13. Hanley, W. D., L. A. Wenning, A. Moreau, J. T. Kost, E. Mangin, T. Shamp, J. A. Stone, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto. 2009. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53:2752-2755.
14. Hariparsad, N., S. C. Nallani, R. S. Sane, D. J. Buckley, A. R. Buckley, and P. B. Desai. 2004. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol. 44:1273-1281.
15. Hartkoorn, R. C., W. S. Kwan, V. Shallcross, A. Chaikan, N. Liptrott, D. Egan, E. S. Sora, C. E. James, S. Gibbons, P. G. Bray, D. J. Back, S. H. Khoo, and A. Owen. 2010. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics 20:112-120.
16. Huang, S. M., J. M. Strong, L. Zhang, K. S. Reynolds, S. Nallani, R. Temple, S. Abraham, S. A. Habet, R. K. Baweja, G. J. Burckart, S. Chung, P. Colangelo, D. Frucht, M. D. Green, P. Hepp, E. Karnaukhova, H. S. Ko, J. I. Lee, P. J. Marroum, J. M. Norden, W. Qiu, A. Rahman, S. Sobel, T. Stifano, K. Thummel, X. X. Wei, S. Yasuda, J. H. Zheng, H. Zhao, and L. J. Lesko. 2008. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48:662-670.
17. Hubatsch, I., E. G. Ragnarsson, and P. Artursson. 2007. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2:2111-2119.
18. Iaccino, E., M. Schiavone, G. Fiume, I. Quinto, and G. Scala. 2008. The aftermath of the Merck's HIV vaccine trial. Retrovirology 5:56.
19. Iwamoto, M., K. Kassahun, M. D. Troyer, W. D. Hanley, P. Lu, A. Rhoton, A. S. Petry, K. Ghosh, E. Mangin, E. P. DeNoia, L. A. Wenning, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J. Clin. Pharmacol. 48:209-214.
20. Iwamoto, M., L. A. Wenning, G. C. Mistry, A. S. Petry, S. Y. Liou, K. Ghosh, S. Breidinger, N. Azrolan, M. J. Gutierrez, W. E. Bridson, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47:137-140.
21. Iwamoto, M., L. A. Wenning, B. Y. Nguyen, H. Teppler, A. R. Moreau, R. R. Rhodes, W. D. Hanley, B. Jin, C. M. Harvey, S. A. Breidinger, N. Azrolan, H. F. Farmer, Jr., R. D. Isaacs, J. A. Chodakewitz, J. A. Stone, and J. A. Wagner. 2009. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48:489-492.
22. Iwamoto, M., L. A. Wenning, A. S. Petry, M. Laethem, M. De Smet, J. T. Kost, S. A. Breidinger, E. C. Mangin, N. Azrolan, H. E. Greenberg, W. Haazen, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 52:4338-4343.
23. Janneh, O., B. Chandler, R. Hartkoorn, W. S. Kwan, C. Jenkinson, S. Evans, D. J. Back, A. Owen, and S. H. Khoo. 2009. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother. 64:1002-1007.
24. Kassahun, K., I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wagner, and L. A. Wenning. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35:1657-1663.
25. Kis, O., K. Robillard, G. N. Chan, and R. Bendayan. 2010. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 31:22-35.
26. Lee, C. G., M. M. Gottesman, C. O. Cardarelli, M. Ramachandra, K. T. Jeang, S. V. Ambudkar, I. Pastan, and S. Dey. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594-3601.
27. Liptrott, N. J., M. Penny, P. G. Bray, J. Sathish, S. H. Khoo, D. J. Back, and A. Owen. 2009. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br. J. Pharmacol. 156:497-508.
28. Luber, A., P. D. Slowinski, and E. Acosta. 2009. Steady-state pharmacokinetics of fosamprenavir and raltegravir alone and combined with unboosted and ritonavir-boosted fosamprenavir, abstr. A1-1297. Abstr. 49th Annu. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
29. Markowitz, M., J. O. Morales-Ramirez, B. Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Liporace, R. Schwartz, R. Isaacs, L. R. Gilde, L. Wenning, J. Zhao, and H. Teppler. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
30. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63. (Pubitemid 14203433)
31. Rizwan, A. N., and G. Burckhardt. 2007. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res. 24:450-470.
32. Sobczak, K., N. Bangel-Ruland, G. Leier, and W. M. Weber. 2010. Endogenous transport systems in the Xenopus laevis oocyte plasma membrane. Methods 51:183-189.
33. Steigbigel, R. T., D. A. Cooper, H. Teppler, J. J. Eron, J. M. Gatell, P. N. Kumar, J. K. Rockstroh, M. Schechter, C. Katlama, M. Markowitz, P. Yeni, M. R. Loutfy, A. Lazzarin, J. L. Lennox, B. Clotet, J. Zhao, H. Wan, R. R. Rhodes, K. M. Strohmaier, R. J. Barnard, R. D. Isaacs, and B. Y. Nguyen. 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin. Infect. Dis. 50:605-612.
34. Summa, V., A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O. Gonzalez Paz, D. J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M. V. Witmer, and M. Rowley. 2008. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51:5843-5855.
35. Takeda, M., S. Khamdang, S. Narikawa, H. Kimura, Y. Kobayashi, T. Yamamoto, S. H. Cha, T. Sekine, and H. Endou. 2002. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300:918-924.
36. Uwai, Y., H. Ida, Y. Tsuji, T. Katsura, and K. Inui. 2007. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24:811-815.
37. van der Sandt, I. C., C. M. Vos, L. Nabulsi, M. C. Blom-Roosemalen, H. H. Voorwinden, A. G. de Boer, and D. D. Breimer. 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS (London) 15:483-491.
38. Wenning, L. A., E. J. Friedman, J. T. Kost, S. A. Breidinger, J. E. Stek, K. C. Lasseter, K. M. Gottesdiener, J. Chen, H. Teppler, J. A. Wagner, J. A. Stone, and M. Iwamoto. 2008. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 52:3253-3258.
39. Wenning, L. A., W. D. Hanley, D. M. Brainard, A. S. Petry, K. Ghosh, B. Jin, E. Mangin, T. C. Marbury, J. K. Berg, J. A. Chodakewitz, J. A. Stone, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto. 2009. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53:2852-2856.
40. Xie, W., M. F. Yeuh, A. Radominska-Pandya, S. P. Saini, Y. Negishi, B. S. Bottroff, G. Y. Cabrera, R. H. Tukey, and R. M. Evans. 2003. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc. Natl. Acad. Sci. U. S. A. 100: 4150-4155.
41. Yilmaz, A., M. Gisslen, S. Spudich, E. Lee, A. Jayewardene, F. Aweeka, and R. W. Price. 2009. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 4:e6877.
42. Zhang, D., T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys. 2005. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33:1729-1739.
43. Zhu, L., L. Mahnke, J. Butterton, A. Persson, M. Stonier, W. Comisar, D. Panebianco, S. Breidinger, J. Zhang, and R. Bertz. 2009. Pharmacokinetics and safety of twice daily atazanavir 300 mg and raltegravir 400 mg in healthy subjects, abstr. 693. Abstr. 16th Conf. Retroviruses Opportun. Infect., Montreal, Canada.